drugset / Trial / NCT03733249

Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study

NCT03733249

Phase 1/2 Terminated 187 enrolled Bellicum Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

This is a long-term follow up study evaluating the safety of BPX-501 T cells (rivogenlecleucel) and infused in pediatric patients previously enrolled on the BP-004 study.

Timeline

Start
2017-01
Primary completion
2020-06-30
Completion
2023-04-14

Drugs

EvaluationDrugModalityDoseRoute
Subject rivogenlecleucel Cell therapy
Background Rimiducid Other / unclassified 0.4 mg/kg Intravenous